Profile data is unavailable for this security.
About the company
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
- Revenue in INR (TTM)119.19m
- Net income in INR-1.06bn
- Incorporated1989
- Employees132.00
- LocationSuven Life Sciences LtdSDE Serene Chambers 6th FloorRoad No. 5 Avenue 7, Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 023541142
- Fax+91 4 023541152
- Websitehttp://www.suven.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 16.75bn | 343.00 | 44.07 | -- | 33.68 | 5.28 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| SMS Pharmaceuticals Ltd | 6.13bn | 360.58m | 17.64bn | 1.10k | 48.87 | -- | 24.38 | 2.88 | 4.26 | 4.26 | 72.40 | -- | -- | -- | -- | 5,597,176.00 | -- | 5.86 | -- | 7.77 | 31.67 | 33.18 | 6.65 | 8.34 | -- | 3.13 | -- | 6.26 | 0.4188 | 2.35 | -111.35 | -- | 28.46 | 3.71 |
| Themis Medicare Ltd | 3.64bn | 452.86m | 19.34bn | 996.00 | 42.78 | -- | 33.77 | 5.31 | 4.91 | 4.91 | 39.49 | -- | -- | -- | -- | 3,655,101.00 | -- | 9.59 | -- | 14.94 | 65.58 | 60.13 | 12.44 | 13.15 | -- | -- | -- | 7.33 | -10.21 | 10.85 | -21.93 | 38.18 | 24.51 | -- |
| Amrutanjan Health Care Ltd | 3.94bn | 440.09m | 19.92bn | 575.00 | 45.58 | -- | 39.97 | 5.05 | 15.13 | 15.13 | 135.41 | -- | -- | -- | -- | 6,860,612.00 | -- | 17.04 | -- | 21.22 | 49.51 | 54.08 | 11.16 | 13.37 | -- | 341.76 | -- | 17.21 | -6.46 | 11.37 | -40.71 | 14.72 | 23.87 | 10.64 |
| Solara Active Pharma Sciences Ltd | 14.07bn | -3.08bn | 20.19bn | 2.36k | -- | -- | -- | 1.43 | -85.65 | -85.65 | 390.73 | -- | -- | -- | -- | 5,958,916.00 | -- | 2.68 | -- | 4.10 | 40.47 | 44.49 | -21.88 | 4.58 | -- | -1.67 | -- | 10.10 | 13.83 | 22.61 | 61.86 | -- | 26.23 | -- |
| Suven Life Sciences Ltd | 119.19m | -1.06bn | 24.77bn | 132.00 | -- | -- | -- | 207.85 | -5.20 | -5.20 | 0.5759 | -- | -- | -- | -- | 902,939.40 | -- | -31.29 | -- | -35.32 | -- | 66.93 | -890.87 | -127.02 | -- | -744.27 | -- | -- | 14.31 | -53.54 | 3.06 | -- | -41.37 | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 25.19bn | 1.23k | -- | 79.68 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Morepen Laboratories Ltd | 16.31bn | 761.19m | 25.58bn | 1.65k | 33.16 | -- | 23.92 | 1.57 | 1.51 | 1.51 | 32.53 | -- | -- | -- | -- | 9,891,111.00 | -- | 7.39 | -- | 13.78 | 35.85 | 32.82 | 4.67 | 5.19 | -- | 27.34 | -- | 0.00 | -8.36 | 18.51 | -61.96 | 5.50 | 11.33 | -- |
| RPG Life Sciences Limited | 5.74bn | 847.70m | 25.61bn | 1.17k | 30.22 | -- | 25.30 | 4.47 | 51.26 | 51.26 | 346.80 | -- | -- | -- | -- | -- | -- | 13.08 | -- | 18.26 | 68.17 | 62.42 | 14.78 | 9.71 | -- | 296.86 | -- | 29.26 | 16.51 | 8.12 | 31.39 | 38.13 | 16.15 | 37.97 |
| Innova Captab Ltd | -100.00bn | -100.00bn | 27.01bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.72 | -- | 6.26 | -- | -- | -- |
| Indoco Remedies Ltd | 17.96bn | 1.02bn | 29.87bn | 6.10k | 29.65 | -- | 16.23 | 1.66 | 10.93 | 10.93 | 192.26 | -- | -- | -- | -- | 2,943,454.00 | -- | 6.07 | -- | 8.90 | 69.39 | 65.35 | 5.61 | 6.30 | -- | 5.11 | -- | 14.79 | 8.30 | 9.81 | -8.11 | 28.15 | 8.25 | 17.61 |
| SeQuent Scientific Ltd | 13.75bn | -1.29bn | 31.12bn | 478.00 | -- | -- | -- | 2.26 | -5.18 | -5.18 | 55.33 | -- | -- | -- | -- | 28,769,920.00 | -- | 2.33 | -- | 3.67 | 42.78 | 42.47 | -8.97 | 2.59 | -- | -0.3894 | -- | 17.27 | 0.5728 | 10.84 | -395.83 | -- | 12.88 | -- |
| Gufic BioSciences Ltd | 7.85bn | 841.95m | 32.16bn | 1.63k | 37.20 | -- | 30.49 | 4.10 | 8.62 | 8.62 | 80.38 | -- | -- | -- | -- | 4,820,074.00 | -- | 12.30 | -- | 23.08 | 51.08 | 44.91 | 10.73 | 9.84 | -- | 8.22 | -- | 1.39 | -11.36 | 17.47 | -16.84 | 37.06 | 86.82 | 14.87 |
| Supriya Lifescience Ltd | 5.54bn | 1.20bn | 33.30bn | 392.00 | 27.64 | -- | 24.61 | 6.01 | 14.97 | 14.97 | 68.93 | -- | -- | -- | -- | 14,144,410.00 | -- | 20.77 | -- | 29.06 | 61.94 | 55.83 | 21.72 | 24.33 | -- | 63.63 | -- | 2.02 | -13.04 | 16.70 | -40.81 | 59.41 | 85.55 | -- |
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Mar 2024 | 2.28m | 1.05% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 766.83k | 0.35% |
| Hamon Asset Management Ltd.as of 30 Sep 2019 | 21.70k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 850.00 | 0.00% |
| Acadian Asset Management LLCas of 30 Sep 2023 | 0.00 | 0.00% |
